Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benza

Showing results (331-340 of 362) with videos related to

Pageof 37
Sort By:
American Journal of Respiratory and Critical Care Medicine|December 10, 2014
Serum endostatin is a genetically determined predictor of survival in pulmonary arterial hypertensionRachel Damico, Todd M Kolb, Lidenys Valera, et al.
Annals of the American Thoracic Society|October 16, 2020
Clinical Differences and Outcomes between Methamphetamine-associated and Idiopathic Pulmonary Arterial Hypertension in the Pulmonary Hypertension Association RegistryNicholas A Kolaitis, Roham T Zamanian, Vinicio A de Jesus Perez, et al.
American Journal of Respiratory and Critical Care Medicine|February 10, 2018
Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. A Joint National Institutes of Health Clinical Center and Pulmonary Hypertension Association Symposium ReportJason M Elinoff, Richa Agarwal, Christopher F Barnett, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|March 29, 2023
Treatment effects of pulmonary artery denervation for pulmonary arterial hypertension stratified by REVEAL risk score: Results from PADN-CFDA trialJuan Zhang, Jing Kan, Yongyue Wei, et al.
The New England Journal of Medicine|March 6, 2023
Transcatheter Repair for Patients with Tricuspid RegurgitationPaul Sorajja, Brian Whisenant, Nadira Hamid, et al.
Circulation|March 30, 2025
Two-Year Outcomes of Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation: The TRILUMINATE Pivotal Randomized Controlled TrialSaibal Kar, Raj R Makkar, Brian K Whisenant, et al.
The Lancet. Respiratory Medicine|May 5, 2024
Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trialRobert P Frantz, Vallerie V McLaughlin, Sandeep Sahay, et al.
The Lancet. Respiratory Medicine|March 27, 2021
Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trialMarius M Hoeper, Hikmet Al-Hiti, Raymond L Benza, et al.
Journal of the American College of Cardiology|October 29, 2024
Tricuspid Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation: 1-Year Outcomes From the TRILUMINATE Randomized CohortGilbert H L Tang, Rebecca T Hahn, Brian K Whisenant, et al.
Advances in Therapy|August 11, 2025
Seralutinib for the Treatment of Pulmonary Arterial Hypertension in Adults: TORREY Open-Label Extension StudyOlivier Sitbon, Sandeep Sahay, Pilar Escribano Subías, et al.
Pageof 37

Showing results (331-340 of 362) with videos related to

Sort By:
Pageof 37
American Journal of Respiratory and Critical Care Medicine|December 10, 2014
Serum endostatin is a genetically determined predictor of survival in pulmonary arterial hypertensionRachel Damico, Todd M Kolb, Lidenys Valera, et al.
Annals of the American Thoracic Society|October 16, 2020
Clinical Differences and Outcomes between Methamphetamine-associated and Idiopathic Pulmonary Arterial Hypertension in the Pulmonary Hypertension Association RegistryNicholas A Kolaitis, Roham T Zamanian, Vinicio A de Jesus Perez, et al.
American Journal of Respiratory and Critical Care Medicine|February 10, 2018
Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. A Joint National Institutes of Health Clinical Center and Pulmonary Hypertension Association Symposium ReportJason M Elinoff, Richa Agarwal, Christopher F Barnett, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|March 29, 2023
Treatment effects of pulmonary artery denervation for pulmonary arterial hypertension stratified by REVEAL risk score: Results from PADN-CFDA trialJuan Zhang, Jing Kan, Yongyue Wei, et al.
The New England Journal of Medicine|March 6, 2023
Transcatheter Repair for Patients with Tricuspid RegurgitationPaul Sorajja, Brian Whisenant, Nadira Hamid, et al.
Circulation|March 30, 2025
Two-Year Outcomes of Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation: The TRILUMINATE Pivotal Randomized Controlled TrialSaibal Kar, Raj R Makkar, Brian K Whisenant, et al.
The Lancet. Respiratory Medicine|May 5, 2024
Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trialRobert P Frantz, Vallerie V McLaughlin, Sandeep Sahay, et al.
The Lancet. Respiratory Medicine|March 27, 2021
Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trialMarius M Hoeper, Hikmet Al-Hiti, Raymond L Benza, et al.
Journal of the American College of Cardiology|October 29, 2024
Tricuspid Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation: 1-Year Outcomes From the TRILUMINATE Randomized CohortGilbert H L Tang, Rebecca T Hahn, Brian K Whisenant, et al.
Advances in Therapy|August 11, 2025
Seralutinib for the Treatment of Pulmonary Arterial Hypertension in Adults: TORREY Open-Label Extension StudyOlivier Sitbon, Sandeep Sahay, Pilar Escribano Subías, et al.
Pageof 37